Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Abbott |
---|---|
Information provided by: | Abbott |
ClinicalTrials.gov Identifier: | NCT00570986 |
Safety and efficacy of ABT-874 in the treatment of moderate to severe plaque psoriasis two doses of ABT-874 versus placebo
Condition | Intervention | Phase |
---|---|---|
Plaque Psoriasis |
Drug: Placebo Biological: ABT-874 |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 3, Multicenter, Randomized, Double-Blind,Placebo-Controlled Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis |
Estimated Enrollment: | 1350 |
Study Start Date: | December 2007 |
Estimated Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Placebo Comparator
Arm #1 is used for entire study. At week 12, arm is rerandomized.
|
Drug: Placebo
Two injections at weeks 0 and 4. One injection at week 8. At week 12, arm is rerandomized to placebo every 4 weeks.
|
2: Active Comparator
Arm #2 is used for entire study. At week 12, arm is rerandomized.
|
Biological: ABT-874
200mg at week 0 and week 4. 100mg at week 8. On week 12, arm is rerandomized to 100mg every 4 weeks.
|
3: Active Comparator
Arm #3 is not used for weeks 0-11. At week 12, arm is rerandomized.
|
Biological: ABT-874
100mg every 12 weeks.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Joaquin Valdes, MD | Abbott |
Responsible Party: | Abbott ( Beverly Paperiello, Director, Immunology Development ) |
Study ID Numbers: | M06-890 |
Study First Received: | December 7, 2007 |
Last Updated: | December 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00570986 |
Health Authority: | United States: Food and Drug Administration |
Plaque Psoriasis |
Skin Diseases Psoriasis Skin Diseases, Papulosquamous |